News & Updates
Showing Pharmacy articles
Showing
Tolebrutinib reduces disability accumulation in relapsing MS
Treatment with tolebrutinib results in a clear reduction in disability accumulation in patients with relapsing multiple sclerosis (MS) compared with teriflunomide despite no difference in relapses, according to the findings of the GEMINI 1 and 2 trials presented at AAN 2025.
Consistent benefits with lecanemab seen in Clarity AD Asian cohort
In the treatment of early Alzheimer’s disease (AD), lecanemab is as safe and efficacious in Asian patients as in the wider Clarity AD population, slowing cognitive decline and reducing amyloid levels in the brain with manageable risks.
Etripamil nasal spray safe, effective against PSVT
Treatment with self-administered etripamil results in the termination of paroxysmal supraventricular tachycardia (PSVT) episodes among Chinese patients in an at-home setting, according to a study presented at EHRA 2025.
3-year RUBY data support add-on dostarlimab as frontline Tx for endometrial cancer
At the second interim analysis of part 1 of the phase III RUBY study, updated duration of response (DoR) findings suggest that women with primary advanced or recurrent endometrial cancer who have achieved a response with the combination regimen comprising dostarlimab and carboplatin-paclitaxel (CP) have substantially improved DoR.
Does CKD reduce tirzepatide benefits on HFpEF patients with obesity?
Long-term treatment with tirzepatide results in improved renal function in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, regardless of the absence or presence of chronic kidney disease (CKD), according to a post hoc analysis of the SUMMIT trial presented at ACC.25.